Two new lipid-regulating drugs
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Question 3
Answer: b. Statins are recommended as initial treatment for all adults with FH. The NICE guidance suggests using a high-intensity statin with the aim of achieving >50% reduction in LDL-C over pretreatment levels.
Evolocumab and alirocumab are the first in a novel class of lipid-regulating drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 
Question 2
Answer: e. PCSK9 is a protein that regulates the recycling of LDL-receptors on the surface of liver cells and decreases the ability of the liver to clear LDL-cholesterol from the blood. Evolocumab and alirocumab bind to PCSK9 and increase recycling of LDL-receptors leading to reduced LDL-cholesterol concentrations.
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Question 4
Answer: c. A network meta-analysis of 17 randomised controlled trials involving 13,083 adults with primary hypercholesterolaemia found that treatment with a PCSK9 inhibitor significantly reduced LDL-C by 57% compared with placebo (p<0.001) and 36% compared with ezetimibe (p<0.001).
